Month: May 2021

Bids, sales, cut-off price, pro rata and yield are presented in the table below:           ISIN Bid mill. DKK (nominal) Sale mill.DKK (nominal) Cut-off price Pro rata Yield99 24292 DGB 0.00% 15/11/2024 14,820 5,015 101.80 44 % -0.50 % p.a.Total 14,820 5,015      Settlement: 7 May 2021

Press Release Nokia launches blockchain-powered Data Marketplace for secure data trading and AI models Designed to enable trusted exchanges and monetization of data via private blockchain Accelerates initiatives in AI and machine learning through federated learning Offers secure multi-party transactions to benefit a wide range of industries 5 May 2021 Espoo, Finland – Nokia today announced the launch of Nokia Data Marketplace as-a-service to facilitate secure sharing of data and AI models, enabling digital transformation and data monetization for enterprises. As data volumes continue to surge, AI and machine learning are increasingly crucial in business decision making. Nokia Data Marketplace is designed to help enterprises and communications service providers (CSPs) use data in strategic decision making, by providing real-time...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 5 May 2021 G4S plc (the “Company”) CANCELLATION OF LISTING AND ADMISSION OF TRADING OF G4S SHARES Further to the announcement by Allied Universal Topco LLC and the Company on 6 April 2021, the Company confirms that the listing of G4S Shares on the premium listing segment of the Official List and the admission of the G4S Shares to trading on the main market of the London Stock Exchange were each cancelled with effect from 8.00 a.m. today. Capitalised terms in this announcement, unless otherwise defined, have the meanings set out in the offer document dated 5 January 2021. Celine Barroche Company Secretary For further enquiries, please...

Interim analysis for critically ill population will be conducted when enrollment reaches about 120 patients or 40% of the approximate 300 patients VANCOUVER, Washington, May 05, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the agreement to partner with Academic Research Organization (ARO) – Albert Einstein Israelite Hospital (AEIH) in São Paulo, Brazil for two COVID-19 trials. The COVID-19 trials in Brazil are intended to provide the Brazilian regulatory authority, ANVISA, with the requisite data to consider advancing the availability of leronlimab to thousands of Brazilians infected with COVID-19. These two Phase...

Aspo Plc                  Interim Report          May 5, 2021 at 10 a.m. Aspo Group Interim Report, January 1 to March 31, 2021 Aspo Q1: Record-high operating profit, relative profitability improved significantly January–March 2021 Figures from the corresponding period in 2020 are presented in brackets.Aspo’s net sales reached the comparative period’s level, being EUR 132.3 (133.2) million. Operating profit increased considerably to EUR 7.9 (4.0) million, driven by the improved results of ESL Shipping and Telko. Profit for the period increased and was EUR 6.4 (2.6) million. Earnings per share increased and were EUR 0.19 (0.07). Operating profit of ESL Shipping was EUR 4.5 (2.3) million, Leipurin EUR 0.3 (0.6) million, and Telko EUR 4.5 (2.4) million. Net cash from operating activities was EUR 6.6 (13.9) million. The impact of the change...

VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce it has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd. (“Akome”), as Chief Medical Officer of the Company. Dr. Ferro will lead the Company through clinical trials and commercialization of its psychedelic products. Dr. Ferro is a graduate of Javeriana University Medical School in his native Bogotá, Colombia, where he specialized in Internal Medicine, and received his sub-specialty training in Infectious Diseases at University of Toronto. Following completion of his medical and specialty training, Dr. Ferro returned to Bogotá and established a private practice in both Internal Medicine and Infectious Diseases, while...

Picture 1In September 2020 the Company filed a provisional patent in the United States for the refinement technique which makes its Beyond Tobacco™ base material taste and smell similarly to actual tobacco. As of this week, the application has been advanced to nonprovisional status, and is currently pending assignment to a patent examiner.LAS VEGAS and VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) — TAAT™ GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “TAAT™”) is pleased to announce that its patent filing with the United States Patent and Trademark Office (“USPTO”) for the technique which causes Beyond Tobacco™ to taste and smell similarly to tobacco has been advanced to “nonprovisional” status, with the assignment of a patent examiner currently pending. In...

SAMPO PLC                INTERIM STATEMENT        5 May 2021 at 9:30 am Sampo Group’s results for January – March 2021         Sampo Group had a strong start to the year in all business areas. Profit before taxes for January – March 2021 rose to EUR 632 million (162) and earnings per share increased to EUR 0.82 (0.26). Mark-to-market earnings per share saw a positive year-on-year increase of more than three euros per share to EUR 1.39 (-1.71). Sampo Group’s core business, P&C insurance, reported the strongest underwriting results in its history. Group underwriting profits grew by 37 per cent year-on-year to EUR 317 million driven by a 4.5 percentage point improvement in the combined ratio to 81.2 per cent (85.7). The result represents a strong first step towards Sampo’s annual financial targets of mid-single digit growth in underwriting...